IQVIA Holdings Inc. (IQV)
After hours:
| Previous close | 213.96 |
| Open | 212.80 |
| Bid | 212.18 x 800 |
| Ask | 212.25 x 800 |
| Day's range | 210.79 - 213.38 |
| 52-week range | 167.42 - 261.73 |
| Volume | |
| Avg. volume | 975,042 |
| Market cap | 38.833B |
| Beta (5Y monthly) | 1.54 |
| PE ratio (TTM) | 29.07 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
IQVIA Launches "One Home" Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites
RESEARCH TRIANGLE PARK, N.C., June 12, 2024--IQVIA (NYSE:IQV) today announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site needs to perform across all of the clinical trials it is conducting.
- Business Wire
IQVIA Institute: Innovative Therapies and Strong Pipeline to Combat Rise in Cancer Diagnoses
RESEARCH TRIANGLE PARK, N.C., June 10, 2024--As cancer incidence continues to rise, it’s being met by wider use of innovative therapies and a robust pipeline of new drugs, according to a new report from the IQVIA Institute for Human Data Science titled, "Global Oncology Trends 2024: Outlook to 2028."
- Business Wire
U.S. Medicines Spending Grew in 2023 as Greater Access Offset COVID-19-related Decline, Says IQVIA Institute
RESEARCH TRIANGLE PARK, N.C., May 14, 2024--Overall spending in the U.S. market for medicines grew by 2.5% and reached $435Bn in 2023. Excluding the contribution from COVID-19 vaccines and therapeutics, spending grew at 9.9%, according to a new report from the IQVIATM Institute for Human Data Science, The Use of Medicines in the U.S. 2024: Usage and Spending Trends and Outlook to 2028.
